Ubs Group Ag Clovis Oncology, Inc. Call Options Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 11, 2021	BUY	$4.13 - $6.41 $243,257 - $377,549	58,900 Added 37.44%	216,200 $1.04 Million
Q1 2020 May 01, 2020	SELL	$3.77 - $11.0 $750,984 - $2.19 Million	-199,200 Reduced 55.88%	157,300 $1 Million
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $895,500 - $4.9 Million	-298,500 Reduced 45.57%	356,500 $3.72 Million
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $679,497 - $2.65 Million	172,900 Added 35.86%	655,000 $2.57 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $5.09 Million - $10.2 Million	397,100 Added 467.18%	482,100 $7.17 Million
Q1 2019 May 14, 2019	BUY	$17.66 - $30.28 $1.5 Million - $2.57 Million	85,000 New	85,000 $2.11 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.